Dr. Louis D. Lieto is the leader of the patents and innovations department at Wilson Sonsini Goodrich & Rosati and is a partner in the firm’s Boston office. Lou advises biotechnology and pharmaceutical companies on strategic patent counseling, global patent portfolio development and management, and IP counseling for M&A and capital markets in complex life science fields.
Lou has decades of experience advising biotechnology, pharmaceutical, and life science clients on all aspects of patent law and related business matters. He works with innovators engaged in highly technical fields, including CRISPR, cell therapy, immunotherapeutics, medical devices, pharmaceuticals, stem cells, biofuels, regenerative medicine, and transgenic animals. He designed and implemented IP Strategy for multiple companies with drugs in active clinical trials, such as Aileron Therapeutics, Charleston Laboratories, Curemark, Gadeta B.V., BioNTech, Myeloid Therapeutics, Stoke Therapeutics, and TCR2 Therapeutics. He has extensive experience representing investors and companies in Financings and M&A.
Lou received his Ph.D. from the University of Kentucky, where he focused on characterizing the molecular and genetic basis of hereditary disease. Subsequently, Lou completed his postdoctoral fellowship in immunology at the National Institute of Allergy and Infectious Diseases (NIAID).
Prior to joining Wilson Sonsini, Lou was a patent examiner at the U.S. Patent and Trademark Office where he examined applications for inventions encompassing proteins, DNA vectors, nucleic acid vaccines, immune cell therapy, stem cell therapy, transgenic animals, and gene therapy.
